Repare Therapeutics Inc. has reached an agreement that will see the company become privately held, with shareholders receiving a cash payment and the opportunity to participate in future milestones and royalties from current and potential partnerships. The board of directors unanimously determined the arrangement to be in the best interests of stakeholders. The transaction is expected to close in the first quarter of 2026, after which Repare's common shares are anticipated to be delisted from the Nasdaq Global Select Market and the company will seek to cease being a reporting issuer in Canada and the United States.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repare Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251114715824) on November 14, 2025, and is solely responsible for the information contained therein.